Literature DB >> 7834453

Raf-1 protein expression in human breast cancer cells.

L S Callans1, H Naama, M Khandelwal, R Plotkin, L Jardines.   

Abstract

BACKGROUND: The Raf-1 kinase, a 72-kDa cytoplasmic serine-threonine kinase, plays a central role as a second messenger in signal transduction. After ligand binding to a variety of transmembrane tyrosine kinase growth factor receptors including epidermal growth factor (EGF) receptor, the 72-kDa kinase is activated through phosphorylation to a 74-kDa phosphoprotein. The Raf-1 kinase is constitutively activated in many transformed cells either directly, by mutations within its amino-terminus regulatory region, or indirectly, due to overstimulation by autocrine growth factors or activated proximal oncogenes. The role of Raf-1 kinase in breast cancer has not been studied.
METHODS: To investigate the role of Raf-1 kinase expression and its activation in breast cancer, we studied three human breast cancer cell lines expressing varying amounts of EGF receptor to determine the level of Raf-1 protein and the proportion expressed in the higher molecular weight form. Effects of serum starvation and stimulation with EGF on the Raf-1 protein were studied in T47D, BT474, and MDA-MB231 cells by precipitation of cell lysates with an anti-Raf-1 antibody followed by immunoblotting. [3H]Thymidine incorporation by these cells after EGF stimulation was also determined as a measure of DNA synthesis.
RESULTS: In all three breast cancer cell lines studied, the Raf-1 protein was identified in a 70- and a 74-kDa form. The level of Raf-1 was similar in all three cell lines and appeared unrelated to EGF receptor expression on the cell surface. The majority of the protein was found in the 74-kDa form even after serum starvation. A minor shift from the lower to higher molecular weight form of Raf-1 was apparent in cells treated with EGF, and increased [3H] thymidine incorporation could be demonstrated in two of the cell lines after EGF stimulation.
CONCLUSION: Baseline expression of the 74-kDa or activated form of the Raf-1 kinase appeared to be elevated in the breast cancer cells studied, indicating constitutive activation. Further investigation into the role of Raf-1 protein in the pathogenesis of breast cancer is indicated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7834453     DOI: 10.1007/bf02303700

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  36 in total

1.  Activation of the MAP kinase pathway by the protein kinase raf.

Authors:  L R Howe; S J Leevers; N Gómez; S Nakielny; P Cohen; C J Marshall
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

2.  Activation of human c-raf-1 by replacing the N-terminal region with different sequences.

Authors:  T Tahira; M Ochiai; K Hayashi; M Nagao; T Sugimura
Journal:  Nucleic Acids Res       Date:  1987-06-25       Impact factor: 16.971

3.  Complementation of byr1 in fission yeast by mammalian MAP kinase kinase requires coexpression of Raf kinase.

Authors:  D A Hughes; A Ashworth; C J Marshall
Journal:  Nature       Date:  1993-07-22       Impact factor: 49.962

4.  Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro.

Authors:  P H Warne; P R Viciana; J Downward
Journal:  Nature       Date:  1993-07-22       Impact factor: 49.962

Review 5.  MAP kinase and the activation of quiescent cells.

Authors:  J V Ruderman
Journal:  Curr Opin Cell Biol       Date:  1993-04       Impact factor: 8.382

6.  Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines.

Authors:  N E Davidson; E P Gelmann; M E Lippman; R B Dickson
Journal:  Mol Endocrinol       Date:  1987-03

7.  Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors.

Authors:  J C Delarue; S Friedman; H Mouriesse; F May-Levin; H Sancho-Garnier; G Contesso
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

8.  Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus.

Authors:  U R Rapp; M D Goldsborough; G E Mark; T I Bonner; J Groffen; F H Reynolds; J R Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide.

Authors:  U Murthy; A Basu; U Rodeck; M Herlyn; A H Ross; M Das
Journal:  Arch Biochem Biophys       Date:  1987-02-01       Impact factor: 4.013

10.  Epidermal growth factor (EGF) stimulates association and kinase activity of Raf-1 with the EGF receptor.

Authors:  H App; R Hazan; A Zilberstein; A Ullrich; J Schlessinger; U Rapp
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

View more
  9 in total

1.  Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.

Authors:  Claudine Isaacs; Pia Herbolsheimer; Minetta C Liu; Mary Wilkinson; Yvonne Ottaviano; Gina G Chung; Robert Warren; Jennifer Eng-Wong; Philip Cohen; Karen L Smith; Karen Creswell; Antonella Novielli; Rebecca Slack
Journal:  Breast Cancer Res Treat       Date:  2010-10-26       Impact factor: 4.872

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

3.  Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.

Authors:  Marc Y Fink; Jerry E Chipuk
Journal:  Genes Cancer       Date:  2013-05

Review 4.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Hyperexpression of mitogen-activated protein kinase in human breast cancer.

Authors:  V S Sivaraman; H Wang; G J Nuovo; C C Malbon
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

Review 6.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Authors:  R I Nicholson; J M Gee
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

7.  Prediction of disease genes using tissue-specified gene-gene network.

Authors:  Gamage Ganegoda; JianXin Wang; Fang-Xiang Wu; Min Li
Journal:  BMC Syst Biol       Date:  2014-10-22

8.  Exosomal miRs in Lung Cancer: A Mathematical Model.

Authors:  Xiulan Lai; Avner Friedman
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

9.  OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: a role for Nck1 but not Nck2.

Authors:  N Winston West; Aileen Garcia-Vargas; Charles E Chalfant; Margaret A Park
Journal:  BMC Cancer       Date:  2013-05-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.